PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 7, 2021Acta cardiologica. Supplementum24 citations

Ticagrelor improves systemic immune-inflammation index in acute coronary syndrome patients

View Full Paper
MAMehmet Koray AdalıPamukkale UniversityİBİpek BüberPamukkale UniversityOKOğuz KılıçKaramanoğlu Mehmetbey University

Structured PICO

Does ticagrelor improve inflammatory parameters (NLR, MHR, PLR, and SII) in PCI-treated ACS patients compared to clopidogrel?

P
Population
Acute coronary syndrome (ACS) patients treated with percutaneous coronary intervention (PCI)
I
Intervention
Ticagrelor
C
Comparator
Clopidogrel
O
Outcome
Inflammatory parameters including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-high-density lipoprotein ratio (MHR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII)surrogate

Ticagrelor may offer additional anti-inflammatory benefits over clopidogrel in patients with acute coronary syndrome undergoing PCI.

Abstract

NLR, MHR, PLR, and SII levels were lower in ACS patients treating with ticagrelor. Ticagrelor may improve these inflammatory parameters in percutaneous coronary intervention (PCI)-treated ACS patients compared to clopidogrel.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Adalı et al. (2021) studied this question.

synapsesocial.com/papers/69effa6fbce9831ba4f73b6fhttps://doi.org/10.1080/00015385.2021.1973770
Ask AI
Helpful
Bookmark
Share
View Full Paper